J. B. Chemicals & Pharmaceuticals Limited Stock NSE India S.E.

Equities

JBCHEPHARM

INE572A01036

Pharmaceuticals

Market Closed - NSE India S.E. 07:40:48 2024-04-29 EDT 5-day change 1st Jan Change
1,907 INR +2.23% Intraday chart for J. B. Chemicals & Pharmaceuticals Limited +6.64% +17.36%

Financials

Sales 2024 * 35.01B 420M 573M Sales 2025 * 40.58B 486M 664M Capitalization 289B 3.47B 4.74B
Net income 2024 * 5.64B 67.61M 92.33M Net income 2025 * 7.06B 84.65M 116M EV / Sales 2024 * 8.3 x
Net Debt 2024 * 1.32B 15.8M 21.58M Net cash position 2025 * 4.41B 52.91M 72.25M EV / Sales 2025 * 7.02 x
P/E ratio 2024 *
48.4 x
P/E ratio 2025 *
38.7 x
Employees 5,095
Yield 2024 *
0.65%
Yield 2025 *
0.77%
Free-Float 45.82%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on J. B. Chemicals & Pharmaceuticals Limited

1 day+2.23%
1 week+6.64%
Current month+15.53%
1 month+12.45%
3 months+12.49%
6 months+36.98%
Current year+17.36%
More quotes
1 week
1 768.25
Extreme 1768.25
1 915.00
1 month
1 651.15
Extreme 1651.15
1 915.00
Current year
1 480.00
Extreme 1480
1 940.00
1 year
875.00
Extreme 875
1 940.00
3 years
671.10
Extreme 671.1
1 940.00
5 years
155.98
Extreme 155.975
1 940.00
10 years
68.05
Extreme 68.05
1 940.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 20-10-04
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 59 20-08-30
Director/Board Member 40 11-06
Director/Board Member 48 21-02-09
More insiders
Date Price Change Volume
24-04-29 1,907 +2.23% 79 262
24-04-26 1,865 +0.12% 72,657
24-04-25 1,863 +2.10% 191,404
24-04-24 1,825 +2.26% 133,182
24-04-23 1,784 -0.21% 113,740

Delayed Quote NSE India S.E., April 29, 2024 at 07:40 am

More quotes
J. B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its therapeutic categories include gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives and pharmacovigilance. The Company's lozenges products include center-filled, soft-centered lozenges; center-filled, powder lozenges; herbal lozenges, and medicated lozenges. The Company offers a complete range of contrast media products including X-ray, MRI, and ultrasound in India as well as internationally. The Company produces a wide range of dosage forms, such as tablets, capsules, liquids, IV infusions, ampoules, vials, ointments, cold rubs, lozenges and sips. Its brands include Rantac OD, RD, Ranraft, Metrogyl ER, Metrogyl O, Nicardia XL, Sporlac EVA and Sporlac G, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
1,864 INR
Average target price
1,882 INR
Spread / Average Target
+0.95%
Consensus